A phase 2 trial in colorectal cancer, run by Shanghai Zhongshan Hospital, now recruiting.
Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma is a phase 2, interventional study registered as NCT05563922 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 56 participants, started 2022-09-01 and due to reach its primary completion in 2025-08-31. Interventions recorded: Total Neoadjuvant Chemoradiotherapy. Conditions listed: Rectal Cancer. Primary outcome: Organ preservation rate at 3 years. Colorectal eligibility wording from the registry: "* cT1-3N0M0 assessed by CT, MRI and ultrasound colonoscopy". Sites: China. No results are recorded here; the registry entry is the source.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.